Free tool
FAERS Monitor: Succinylcholine Chloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215143 or its brand name (Succinylcholine Chloride, Succinylcholine Chloride). Reports on generic versions are filed under their own applications.
Reports
2,012
Serious
1,725
86% of reports
Hospitalization
696
Death reported
234
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective232
- hypotension177
- cardiac arrest160
- anaphylactic shock146
- drug interaction126
- anaphylactic reaction111
- renal failure99
- renal impairment99
- hyperthermia malignant98
- pain96
- maternal exposure during pregnancy91
- injury87
- anxiety85
- rhabdomyolysis81
- unevaluable event79
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 91 |
| 2005 | 29 |
| 2006 | 40 |
| 2007 | 48 |
| 2008 | 44 |
| 2009 | 54 |
| 2010 | 71 |
| 2011 | 190 |
| 2012 | 90 |
| 2013 | 27 |
| 2014 | 22 |
| 2015 | 44 |
| 2016 | 67 |
| 2017 | 93 |
| 2018 | 85 |
| 2019 | 148 |
| 2020 | 148 |
| 2021 | 125 |
| 2022 | 124 |
| 2023 | 122 |
| 2024 | 105 |
| 2025 | 159 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,147 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperthermia malignantSignal | 98 | 737.2 | 603.5 | 66,624 |
| anaphylactic shockSignal | 146 | 59.5 | 50.9 | 8,309 |
| anaphylactic reactionSignal | 111 | 21.0 | 17.6 | 2,100 |
| rhabdomyolysisSignal | 81 | 20.3 | 16.4 | 1,471 |
| cardiac arrestSignal | 160 | 20.3 | 17.5 | 2,922 |
| injurySignal | 87 | 13.0 | 10.5 | 950 |
| renal impairmentSignal | 99 | 12.3 | 10.2 | 1,023 |
| unevaluable eventSignal | 79 | 10.9 | 8.8 | 704 |
| maternal exposure during pregnancySignal | 91 | 10.7 | 8.7 | 792 |
| hypotensionSignal | 177 | 9.2 | 8.0 | 1,302 |
| drug interactionSignal | 126 | 8.3 | 7.0 | 808 |
| renal failureSignal | 99 | 7.8 | 6.4 | 583 |
| anxietySignal | 85 | 3.1 | 2.5 | 122 |
| drug ineffective | 232 | 1.8 | 1.6 | 94 |
| pain | 96 | 1.6 | 1.3 | 24 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.